检索结果-南通市图书馆

和厚朴酚对急慢性应激小鼠的抗抑郁作用及机制研究

在线全文

学校读者我要写书评

暂无评论

中国药学杂志 2017年第24期52卷 2161-2165页

作者：王萍萍刘保秀杨桃李丽娜王淑艳畅洪昇北京中医药大学中药学院北京100102 北京中医药大学基础医学院北京100102 北京中医药大学中医学院北京100102

目的研究和厚朴酚对急慢性应激小鼠的抗抑郁作用及其机制。方法采用强迫游泳急性应激小鼠模型(FST)及慢性应激小鼠模型。急性应激小鼠随机分为对照组、氟西汀组(3.3 mg·kg-1)、和厚朴酚组(2.5,5,10 mg·kg-1);慢性应激小鼠随机分为空... 详细信息

目的研究和厚朴酚对急慢性应激小鼠的抗抑郁作用及其机制。方法采用强迫游泳急性应激小鼠模型(FST)及慢性应激小鼠模型。急性应激小鼠随机分为对照组、氟西汀组(3.3 mg·kg-1)、和厚朴酚组(2.5,5,10 mg·kg-1);慢性应激小鼠随机分为空白组、模型组、氟西汀组(3.3 mg·kg-1)、和厚朴酚组(2.5,5,10 mg·kg-1),观察小鼠强迫游泳不动时间,采用Elisa试剂盒检测小鼠脑组织中5-羟色胺(5-HT)及吲哚2,3-双加氧酶(IDO)含量。采用实时荧光定量PCR检测慢性应激小鼠脑组织中IDO mRNA的表达情况。结果急慢性应激小鼠各给药组强迫游泳不动时间明显缩短(P<0.05);和厚朴酚中、高剂量组可增加FST小鼠模型脑5-HT含量(P<0.05,P<0.01),高剂量组明显减少FST小鼠模型脑IDO含量(P<0.05);和厚朴酚低、中、高剂量组明显增加慢性应激小鼠脑组织5-HT含量,减少脑组织IDO含量,明显降低IDO mRNA表达水平,与模型组相比具有统计学差异(P<0.05)。结论和厚朴酚可以改善小鼠抑郁行为,具有一定抗抑郁作用,其主要作用机制与降低色氨酸通路限速酶IDO含量及基因表达水平,促进色氨酸转化为5HT,增加大脑中5-HT水平有关。

关键词：和厚朴酚抗抑郁作用机制

Reproductive Biology of Boiga guangxiensis Wen,1998(Serpentes:Colubridae)

在线全文

学校读者我要写书评

暂无评论

Asian Herpetological Research 2010年第1期1卷 44-47页

作者： Sergei A.Ryabov Nikolai l.Orlov Tula Exotarium Oktyabrskaya26Tula 300002Russia Zoological Institute Russian Academy of SciencesUniversitetskaya Nab. 1St. Petersburg 199034Russia

Up to now, the reproductive biology of most species of the genus Boiga is investigated very little. Important data on the reproductive biology of Boiga guangxiensis were received by us for the first time. The investigations were carried out in Viet Nam during expeditions and in the laboratories of Tula Exotarium in the period between 1998-2000. The data on the feeding, egg size, incubation, size of hatchings, and juvenile colouration of this species are provided for the first time. In addition, the data on size and ratio of snout-vent length/tail length of this snake are provided based on the Vietnamese samples. Our researches demonstrated that B. guangxiensis is distinguished from most other species of the genus by a number of peculiarities of its reproductive biology. Also, morphological differences between Chinese and Vietnamese individuals of this species were noted.

关键词： Boiga guangxiensis reproduction juvenile colouration Viet Nam

Neoadjuvant treatment for resectable pancreatic adenocarcinoma

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Oncology 2016年第1期7卷 1-8页

作者： John Wong Naveenraj l Solomon Chung-Tsen Hsueh Division of Medical Oncology and Hematology Department of Internal Medicine Loma Linda University Department of Surgery Loma Linda University

Pancreatic adenocarcinoma is the fourth leading cause of cancer mortality in the United States in both men and women, with a 5-year survival rate of less than 5%. Surgical resection remains the only curative treatment, but most patients develop systemic recurrence within 2 years of surgery. Adjuvant treatment with chemotherapy or chemoradiotherapy has been shown to improve overall survival, but the delivery of treatment remains problematic with up to 50% of patients not receiving postoperative treatment. Neoadjuvant therapy can provide benefits of eradication of micrometastasis and improved delivery of intended treatment. We have reviewed the findings from completed neoadjuvant clinical trials, and discussed the ongoing studies. Combinational cytotoxic chemotherapy such as fluorouracil, leucovorin, irinotecan, and oxaliplatin and gemcitabine plus nanoparticle albumin-bound(nab)-paclitaxel, active in the metastatic setting, are being studied in the neoadjuvant setting. In addition, novel targeted agents such as inhibitor of immune checkpoint are incorporated with cytotoxic chemotherapy in early-phase clinical trial. Furthermore we have explored the utility of biomarkers which can personalize treatment and select patients for target-driven therapy to improve treatment outcome. The treatment of resectable pancreatic adenocarcinoma requires multidisciplinary approach and novel strategies including innovative trials to make progress.

关键词： Pancreatic cancer Resectable pancreatic adenocarcinoma Neoadjuvant treatment Biomarkers Chemotherapy Surgery

Toward a Phylogeny of the Kukri Snakes,Genus Oligodon

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Herpetological Research 2010年第1期1卷 1-21页

作者： Marc D.Green Nikolai l.Orlov Robert W.Murphy Department of Natural History Royal Ontario Museum100 Queen’s Park TorontoON M5S 2C6 Canada Zoological Institute Russian Academy of SciencesUniversitetskaya nab 1 St.Petersburg 199034Russia State Key laboratory of Genetic Resources and Evolution Kunming Institute of ZoologyChinese Academy of Sciences

The South and Southeast Asian snake genus Oligodon, known for its egg-eating feeding behavior, has been a taxonomically and systematically challenging group. This work provides the first phylogenetic hypothesis for the genus. We use approximately 1900 base pairs of mitochondrial DNA sequence data to infer the relationships of these snakes, and we examine congruence between the phylogeny and hemipenial characters. A hypothesis for the position of Oligodon within the Colubridae is also proposed. We discuss the implications of the phylogeny for previous taxonomic groupings, and consider the usefulness of the trees in analysis of behavior and biogeography of this genus.

关键词： Oligodon genealogy Colubridae hemipenis mitochondrial DNA Southeast Asia South Asia

A New Species of Microhyla(Amphibia:Anura:Microhylidae)from langbian Plateau,Central Vietnam

在线全文

学校读者我要写书评

暂无评论

Asian Herpetological Research 2020年第3期11卷 161-182页

作者： Van Chung HOANG Mai Anh lUONG Quang Truong NGUYEN Nikolai l.ORlOV Youhua CHEN Bin WANG Jianping JIANG Chinese Academy of Sciences(CAS)Key laboratory of Mountain Ecological Restoration and Bioresource Utilization and Ecological Restoration and Biodiversity Conservation Key laboratory of Sichuan Province Chengdu Institute of BiologyCASChengdu 610041China University of Chinese Academy of Sciences Beijing 100049China Vietnam National Museum of Nature Vietnam Academy of Science and Technology18 Hoang Quoc Viet RoadHanoiVietnam Institute of Ecology and Biological Resources Vietnam Academy of Science and Technology18 Hoang Quoc Viet RoadHanoiVietnam Graduate University of Science and Technology Vietnam Academy of Science and Technology18 Hoang Quoc Viet RoadCau GiayHanoiVietnam Zoological Institute Russian Academy of SciencesUniversitetskaya nab 1St.Petersburg 199034Russia

We describe a new species,Microh yla hongiaoensis ***.,from lam Dong Province,southern Vietnam based on morphological data and molecular *** new species is sister to *** by molecular phylogenetics and also most closely resembles *** in morphological characteristics,albeit differs from its congeners by a combination of the following morphological features:(1)size medium(SVl 13.6-14.7 mm in males and 18.3-18.6 mm in females);(2)fingers Ⅱ-Ⅳ with small disks,dorsal surface of disks,without median longitudinal groove;(3)webbing formula Ⅰ11/2 Ⅱ1-2 Ⅲ1-21/2Ⅳ21/4-1 Ⅴ;(4)toe disks with dorsal median longitudinal groove;(5)dorsal back without two small black spots;(6)one small black spot adjacent behind the eyes;(7)few small black scapular spots in the flanks-belly and inguinal region;(8)palm with two small metatarsal tubercles;(9)tibiotarsal reaching beyond *** *** in evergreen montane tropical forests at an elevation of 1500 m a.s.l.

关键词： new species Microhyla Bi Doup-Nui Ba national

单扫描示波极谱法测定皮蛋中微量铅的方法研究

在线全文

学校读者我要写书评

暂无评论

唐山学院学报 2011年第6期24卷 40-43页

作者：杨习居罗望李颖娜唐山学院专科教育部管理系河北唐山063000 唐山学院环境与化学工程系河北唐山063000

在0.01g/ml碘化钾,0.016g/ml酒石酸钾钠,0.001g/ml抗坏血酸,0.24mol/l盐酸底液中,采用单扫描示波极谱法获得铅和碘络合物吸附波,用于皮蛋中微量铅的测量。文中讨论了碘化钾、酒石酸钾钠、抗坏血酸、盐酸的加入量及静止时间对反应的影响... 详细信息

在0.01g/ml碘化钾,0.016g/ml酒石酸钾钠,0.001g/ml抗坏血酸,0.24mol/l盐酸底液中,采用单扫描示波极谱法获得铅和碘络合物吸附波,用于皮蛋中微量铅的测量。文中讨论了碘化钾、酒石酸钾钠、抗坏血酸、盐酸的加入量及静止时间对反应的影响从而确定了适宜的实验条件。实验表明,铅在此底液中峰电位在-520mV,峰电流与铅离子的浓度在0.2～1.0μg/ml范围内呈良好的线性关系,线性回归方程为:Iy=2 492.2Cx+332.1,相关系数r2=0.999 4。回收率为98.4%～103.9%。此方法测定皮蛋中微量铅,仪器简单,操作快速、简便,准确度高,测定结果令人满意。

关键词：单扫描示波极谱法吸附波皮蛋铅

FOlFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第31期22卷 6987-7005页

作者： Chiara Caparello laura l Meijer Ingrid Garajova Alfredo Falcone Tessa Y le large Niccola Funel Geert Kazemier Godefridus J Peters Enrico Vasile Elisa Giovannetti University Hospital of Pisa 56124 Pisa Italy Department of Medical Oncology VU University Medical Center 1081 HV Amsterdam The Netherlands Department of Surgery VU University Medical Center 1081 HV Amsterdam The Netherlands Department of Experimental Diagnostic and Speciality Medicine University of Bologna Sant'Orsola-Malpighi Hospital Via Massarenti 9 40138 Bologna Italy Cancer Pharmacology lab AIRC Start-Up Unit University of Pisa 56124 Pisa Italy CNR-Nano Institute of Nanoscience and Nanotechnology University of Pisa 56124 Pisa Italy

Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOlFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase Ⅲ trial showing an improved outcome over gemcitabine, the combination of gemcitabine/nab-paclitaxel emerged as another standard first-line treatment. However, this treatment is also associated with more side effects. In addition, despite initial promising data on the predictive role of SPARClevels, recent studies showed that these levels are not associated with nab-paclitaxel efficacy. The choice to use this treatment over FOlFIRINOX is therefore a topic of debate, also because no validated biomarkers to guide FOlFIRINOX treatment are available. In the era of actionable mutations and target agents it would be desirable to identify molecular factors or biomarkers to predict response to therapy in order to maximize the efficacy of treatment and avoid useless toxic effects for non-responding patients. However, until today the milestone of treatment for pancreatic cancer remains chemotherapy combinations, without predictive or monitoring tools existing to optimize therapy. This review analyzes the state-of-the-art treatments, promises and limitations of targeted therapies, ongoing trials and future perspectives, including potential role of microR NAs as predictive biomarkers.

关键词： FOlFIRINOX Personalized therapy New treatments MicroR NA Pancreatic cancer

New challenges in perioperative management of pancreatic cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第8期21卷 2281-2293页

作者： Francesco Puleo Raphaёl Maréchal Pieter Demetter Maria-Antonietta Bali Annab.lle Calomme Jean Closset Jean-Baptiste Bachet Jacques Deviere Jean-luc Van laethem Department of Gastroenterology and Digestive Oncology Erasme Hospital laboratory of Experimental Gastroenterology Free University of Brussels Department of Pathology Erasme Hospital Department of Radiology Erasme Hospital Department of Hepatogastroenterology Pitié Salpêtrière Hospital

Pancreatic ductal adenocarcinoma(PDAC)is the fourth leading cause of cancer-related death in the industrialized *** progress in the understanding of the molecular and genetic basis of this disease,the5-year survival rate has remained low and usually does not exceed 5%.Only 20%-25%of patients present with potentially resectable disease and surgery represents the only chance for a *** decades of gemcitabine hegemony and limited therapeutic options,more active chemotherapies are emerging in advanced PDAC,like 5-Fluorouracil,folinic acid,irinotecan and oxaliplatin and nab-paclitaxel plus gemcitabine,that have profoundly impacted therapeutic *** is considered a systemic disease because of the high rate of relapse after curative surgery in patients with resectable disease at *** strategies in resectable,borderline resectable,or locally advanced pancreatic cancer may improve *** of tissue biomarker testing and imaging techniques into preoperative strategies should allow clinicians to identify patients who may ultimately achieve curative benefit from *** review summarizes current knowledge of adjuvant and neoadjuvant treatment for PDAC and discusses the rationale for moving from adjuvant to preoperative and perioperative therapeutic strategies in the current era of more active chemotherapies and personalized *** also discuss the integration of good specimen collection,tissue biomarkers,and imaging tools into newly designed preoperative and perioperative strategies.

关键词： Neoadjuvant chemotherapy Biomarkers Preoperative s

EGFR敏感型肺腺癌38例TKIs治疗前及进展后EGFR基因变化分析

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

诊断病理学杂志 2019年第1期26卷 1-6页

作者：董宇杰刘子臣李琨王宇轩宋婧苏丹车南颖马丽首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所病理科北京101149 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所耐药结核病研究北京市重点实验室北京101149 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所肿瘤内科北京101149

目的观察表皮生长因子受体(EGFR)敏感型肺腺癌患者EGFR-TKIs治疗前及进展后EGFR基因变化情况,分析其导致耐药的可能机制。方法回顾性分析38例EGFR-TKIs治疗前及进展后均进行活检取材的肺腺癌患者,所有病例均采用ARMS法检测腺癌组织EGFR... 详细信息

目的观察表皮生长因子受体(EGFR)敏感型肺腺癌患者EGFR-TKIs治疗前及进展后EGFR基因变化情况,分析其导致耐药的可能机制。方法回顾性分析38例EGFR-TKIs治疗前及进展后均进行活检取材的肺腺癌患者,所有病例均采用ARMS法检测腺癌组织EGFR和KRAS基因突变状态。结果 38例肺腺癌患者中,临床分期为ⅠA期1例,ⅢA期3例,ⅢB期2例,Ⅳ期32例。EGFR-TKIs治疗前,27例患者检测出EGFR基因19外显子缺失突变(19-del),11例患者检测出EGFR基因21外显子l858R点突变(l858R); EGFR-TKIs治疗进展后,17例患者EGFR基因突变状态没有改变(15例19-del和2例l858R); 19例患者检测出EGFR基因20外显子T790M点突变(T790M),其中12例19-del+T790M双突变,6例l858R+T790M双突变; 1例患者的EGFR基因l858R突变改变为19-del+l858R+T790M复合突变; 1例患者的EGFR基因l858R突变改变为KRAS基因突变(G12 V),1例患者的EGFR基因l858R突变改变为EGFR基因野生型。此外,有2例患者EGFR-TKIs治疗进展后,病理组织学中发现了小细胞癌成分。28例患者给予EGFR-TKIs治疗进展后,T790M突变阳性的患者疾病无进展生存时间为18个月,T790M突变阴性的患者为9个月,差异显著(P <0. 05)。结论 T790M突变是导致EGFR基因产生EGFR-TKIs耐药的主要突变类型,然而EGFR基因也可因发生KRAS基因突变、EGFR敏感突变位点发生丢失或改变等变化而产生耐药。

关键词：肺腺癌表皮生长因子受体耐药